Arabic Arabic English English French French German German
dark

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rwanda and Senegal to Improve Long-Term Vaccine Supply

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) agreed today to evaluate the establishment of sustainable vaccine manufacturing capabilities in Rwanda and Senegal to support vaccine supply for the Member States of the African Union. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

WHO’s Science in 5 on COVID-19: Breastfeeding & COVID-19

Next Post

TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer

Related Posts
Total
0
Share